Solriamfetol Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 75 mg, 150 mg
Reference Brands: Sunosi (USA/EU)
Category:
Antipsychotropic Drugs
Solriamfetol is available in Tablets
and strengths such as 75 mg, 150 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Solriamfetol is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Solriamfetol can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Solriamfetol is a wakefulness-promoting medication used for the treatment of excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea. It acts as a dopamine and norepinephrine reuptake inhibitor, helping increase alertness and improve the ability to stay awake during the day. Unlike traditional stimulants, solriamfetol has a targeted mechanism that supports sustained wakefulness with a controlled effect on central nervous system pathways.
The medicine is taken orally and is intended to improve daytime functioning in patients whose sleepiness persists despite appropriate management of underlying conditions, such as continuous positive airway pressure (CPAP) therapy for obstructive sleep apnea. Clinical studies have shown that solriamfetol provides meaningful improvement in wakefulness and daily performance measures, and in some comparisons it has demonstrated stronger effects on excessive daytime sleepiness than several other wakefulness-promoting agents. It is marketed under the brand name Sunosi and is approved in multiple regions for adult use under medical supervision, with dosing individualized based on response and tolerability.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing